Investigation of Performance and Compatibility of the Baxter Dialyzer Xenium XPH 210 During On-line Hemodiafiltration
Launched by PRAXISVERBUND DIALYSE UND APHERESE · Sep 14, 2009
Trial Information
Current as of May 06, 2025
Completed
Keywords
ClinConnect Summary
The new high flux dialyser membrane Xenium XPH 210 from Baxter will show an considerably increased removal of ß2-Microglobulin with olHDF in post dilution mode together with a markedly increased removal of small molecules (urea, creatinine, phosphate). The loss of albumin will depend on the treatment modalities. However, the albumin permeability is tolerable over the whole range of total filtration rate selected and applied to the patients.
Together with the albumin loss into the filtrate/dialysate a small amount of albuminbound substances is detectable.
Parameters of micro-inflammation c...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who have signed an informed consent form.
- • Patients between 18 and 75 years.
- • Patients who have been treated with hemodialysis for more than three months.
- • Patients who are treated three times a week for 4-5 hours.
- • Patients who are usually treated with high-flux dialyzers.
- • Patients who are on a stable anticoagulation and erythropoetin regimen.
- • Patients whose hematocrit is over 28 %.
- • Patients having no vascular access related problems.
- Exclusion Criteria:
- • Patients not meeting the inclusion criteria.
- • Patients who are in a poor nutritional status as judged by the investigator.
- • Patients in a gravid state.
- • Patients with an unstable clinical condition (e.g. cardiac or vascular instability).
- • Patients whose life expectancy is less than 12 months.
- • Patients with a positive anamnesis for the first use syndrome.
- • Patients with known coagulation problems.
- • Patients who receive hemodialysis via a single dialysis needle or central venous catheter.
- • Patients participating in another study that may interfere with the outcome of the present study.
About Praxisverbund Dialyse Und Apherese
Praxisverbund Dialyse und Apherese is a leading clinical trial sponsor specializing in the fields of nephrology and apheresis therapies. Committed to advancing patient care, the organization focuses on innovative research that enhances treatment outcomes for individuals with renal conditions. Through collaborative partnerships with healthcare professionals and research institutions, Praxisverbund Dialyse und Apherese aims to facilitate rigorous clinical trials that adhere to the highest ethical and scientific standards. Their dedication to evidence-based practices and patient-centered research positions them as a trusted entity in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rostock, , Germany
Patients applied
Trial Officials
Peter G. Ahrenholz, PhD
Principal Investigator
BioArtProducts GmbH Rostock, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials